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A simple and inexpensive method for functionalization of preformed liposomes is presented. Soy sterol–PEG1300 ethers are activated by
tresylation at the end of the PEG chain. Coupling of bovine serum albumin as an amino group containing model ligand to the activated lipids can
be performed at pH 8.4 with high efficiency. At room temperature, the mixture of sterol–PEG and sterol–PEG–protein inserts rapidly into the
outer liposome monolayer with high efficiency (N100 μg protein/μmol total lipid). This method of post-functionalization is shown to be effective
with fluid or rigid and plain or pre-PEGylated liposomes (EPC/Chol, 7:3; HSPC/Chol 2:1, and EPC/Chol/MPEG2000–DSPE 2:1:0.16 molar
ratios). The release of entrapped calcein upon the insertion of 7.5 mol% of the functionalized sterols is lower than 4%. Incubation of post-
functionalized liposomes with serum for 20 h at 37 °C shows stable protein attachment at the liposome surface.
© 2005 Elsevier B.V. All rights reserved.Keywords: Liposome; Sterical stabilization; Soy sterol-poly(ethyleneglycol); Tresylation; Protein coupling; Specific targeting1. Introduction
Liposomes are artificial membrane vesicles which can be
used as either passive or specifically targeted drug carrier
systems. While the vesicle itself can be used for carrying
pharmaceuticals [1] or enzymes [2], the surface of the liposome
can be modified through the use of targeting motifs in order to
ensure site-specific drug delivery. The grafting of hydrophilic
polymers can help to avoid the rapid clearance of liposomes
from the blood stream [3,4,10,11]. This is usually accomplished
by the insertion of poly(ethyleneglycol) (PEG) derivatives ofAbbreviations: BSA, bovine serum albumin; Chol, cholesterol; DSPE, 1,2-
distearoyl-sn-glycero-3-phosphoethanolamine; EPC, egg phosphatidylcholine;
HBS, HEPES-buffered saline; HSPC, hydrogenated soy phosphatidylcholine;
MAL-PEG–DSPE, 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[mal-
eimido-poly(ethyleneglycol)]; MPEG2000–DSPE, 1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-N-[methoxy-poly(ethyleneglycol)-2000]; PCS, photon
correlation spectroscopy; PEG, poly(ethylene glycol); sterol–PEG1300, soy
sterol-poly(ethyleneglycol)-1300-ether; TEA, triethylamine; THF, tetrahydro-
furan; tresylchloride, 2,2,2-trifluoroethanesulfonylchloride; TL, total lipid;
TLC, thin layer chromatography
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doi:10.1016/j.bbamem.2005.12.010phosphatidylethanolamine [3,4] or PEG-cholesterol [4–9] into
the vesicle surface.
Furthermore, addition of functionalized PEG-phospholipids
to the lipid mixture makes the supplementary attachment of cell-
targeting molecules containing amino groups such as proteins
(e.g. antibodies), peptides or ligands possible. Various activating
strategies have been described in the literature. While MAL-
PEG-DSPE [12,13] or pyridyldithiol-PEG-PE [14,15] may
be used for the attachment of thiolated homing devices, p-
nitrophenyl-PEG-PE [16] or lipids functionalized with cyanuric
chloride [17] are useful for the coupling of amino-group con-
taining ligands.
A common method used in the preparation of sterically
stabilized immunoliposomes is the simple mixing of activated
PEG-lipids with other membrane components prior to vesicle
preparation. This conventional approach for the preparation of
targeted liposomes is associated not only with exposure of
the functionalized lipid-PEG derivatives, but their possible
chemical reaction with other membrane components or the
encapsulated drugs themselves. This of course limits the useful-
ness of this procedure. Another disadvantage of this method,
especially for smaller liposomes, is a reduction in the trapping
efficiency of the material to be encapsulated due to the space
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[18].
The so-called post-insertion technique was developed re-
cently [19–22] in order to overcome these difficulties. This
approach for preparing targeted liposomes makes use of the
spontaneous incorporation of PEG-PE-lipids from the
micellar phase into pre-formed and even drug-loaded liposomes
[23–26]. This avoids the interference of activated lipids with
other liposomal components such as buffer components, since
the derivatization of the targeting molecule to be attached to the
liposome surface takes place in a separate step. Furthermore, the
surface modification of pre-formed liposomes provides a basis
to specifically modify liposomal formulations currently on the
market (e.g. Doxil®, Myocet®) with respect to the therapeutic
needs of the individual patient [19].
A limitation of this technique is the requirement for an in-
crease in temperature during the incorporation procedure as a
result of poor transfer kinetics for PEG-PE-lipids at ambient
temperature. Temperatures of 60 °C, if maintained for 1 h as
suggested, may be associated with a loss in activity of coupled
proteins or peptides and/or the encapsulated or membrane-
incorporated drug. Furthermore, the net negative surface charge
in liposomes containing PEG-PE has been shown to decrease the
level of endocytosis in carcinoma cells [27].
In this study, we present the synthesis of tresylated PEG-
sterols and show their suitability when used in the coupling of
proteins at the distal end of the PEG-moiety. In a subsequentFig. 1. Chemical activation of sterol–PEG1300 (a) by tresylchloride (b). The resultingstep, the lipid–ligand conjugates can then be effectively inserted
at ambient temperature into pre-formed liposomes of various
fluid or rigid membrane compositions and even into pre-PEGy-
lated vesicles.
2. Materials and methods
2.1. Materials
Bovine serum albumin (BSA) was purchased from Merck, Darmstadt,
Germany. BPS-30 was a generous gift from Nikko Chemicals (Tokyo, Japan).
Cholesterol (Chol) was purchased from Sigma (Deisenhofen, Germany), egg
phosphatidylcholine (EPC, N98% purity) and hydrogenated soy phosphatidyl-
choline (HSPC, N98% purity) were a generous gift from Lipoid (Ludwigshafen,
Germany). 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy-poly
(ethylene glycol)-2000] (MPEG2000–DSPE) was obtained from Genzyme
Pharmaceuticals (Liestal, Switzerland), histidine–HCl from Merck (Darmstadt,
Germany), triethylamine (TEA), tetrahydrofuran (THF), 2,2,2-trifluorethane-
sulfonylchloride (tresylchloride) from Fluka (Buchs, Switzerland), Sepharose
CL-4B from Pharmacia Biotech (Uppsala, Sweden), IODO Beads from Pierce
(Rockford, USA) and carrier free Sodium 125Iodine from Hartmann Analytic
(Braunschweig, Germany).
2.2. Purification of sterol–PEG1300
Sterol–PEG1300 (Fig. 1a) mainly consisting of PEG ethers (mean
oxyethylene number: 30, i.e., Mw of PEG, 1320) from soy sterols (sitosterol:
campesterol: stigmasterol in a molar ratio of 2:1:1) was effectively separated
from free PEG (2–5 wt.%) and further impurities by micellar chromatography
on a Sepharose CL-4B column (3.5×10 cm) using water as eluent. 500 mg of
BPS-30 dissolved in water (100 mg/ml) was fractionated in 2.5–5 ml samples.sterol–PEG1300–TRE (c) is coupled to BSA by acylation (d) or alkylation (e).
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developed with chloroform/methanol (85/15; v/v). Spots were visualized by
Dragendorff's reagent R [Ph. Eur. 5.2]. Fractions without free PEG were pooled
and freeze-dried yielding approximately 300 mg of purified sterol–PEG1300.
2.3. Synthesis of tresylated sterol–PEG1300 (sterol–PEG1300–TRE)
The tresylation of sterol–PEG1300–TRE was done in principle as described
by Nilson and Mosbach [28]. 500 mg (0.29 mmol) of purified sterol–PEG1300
and 120 μl (0.87 mmol) of triethylamine (TEA) were dissolved in 10 ml of dried
THF. The solution was cooled down to 0 °C and 64 μl (0.58 mmol) of
tresylchloride (Fig. 1b) in 5 ml of THF were added dropwise under nitrogen
atmosphere. The reaction was allowed to continue at room temperature with
constant stirring for 4 h, after which the TEA salts were removed by filtration.
The filtrate was rotary evaporated under reduced pressure and redissolved in a
small amount of diethylether. The solution was stored at −27 °C overnight and
the white precipitate was collected by centrifugation at −10 °C. The pellet was
redissolved in chloroform and then further purified by column chromatography
(3.5×10 cm) on silica gel 60 using chloroform/methanol (85/15; v/v) as an
eluent. The fractions containing the product were pooled and vacuum-dried
overnight to yield approximately 300 mg tresylated sterol–PEG1300 (sterol–
PEG1300–TRE, Fig. 1c). Stored under a nitrogen atmosphere at −27 °C and
when monitored by 1H NMR, it was stable for at least 6 months (data not
shown).
Mean Mw: 1880; 1H NMR (300 MHz, CDCl3): δ 5.55 (s, 1H, –C=CH–
sterol), 4.52 (m, 2H, CH2OSO2), 4.22 (q, 2H,
3JH,F=9.0 Hz, CH2CF3); 3.61 (m,
oxyethylene–CH2), 0.68–2.5 (m, sterol–CH).
2.4. Liposome preparation
Liposomes were prepared by the film method using EPC/Chol (molar ratio
7:3) or HSPC/Chol (molar ratio 2:1) representing liquid-crystalline (Lα) or gel
(Lβ) membrane phases at room temperature, respectively. A third kind of
liposome was prepared following the membrane composition of liposomal
doxorubicin (Doxil®) and consisted of HSPC/Chol/MPEG2000–DSPE (molar
ratio 2:1:0.16).
Lipids were dissolved in CHCl3/MeOH (3:1 v/v) and the solvent was rotary
evaporated to dryness. The film was hydrated using the appropriate volume of
HBS (HEPES buffered saline, HEPES 20 mM, NaCl 130 mM, pH 7.4), resulting
in the formation of multilamellar vesicles. The raw vesicle dispersion was sized
down and transformed to almost unilamellar liposomes by subsequent extrusion
(LiposoFast, Avestin, Ottawa, Canada) eleven times each through 200 nm and
80 nm pores of polycarbonate membranes (Nuclepore; Pleasanton, USA).
Particle size was determined by photon correlation spectroscopy (Zetamaster S,
Malvern, Herrenberg, Germany; auto analysis option, Malvern Software Version
1.4.1) to be within a range of 115 to 125 nm with a polydispersity index below
0.12.
2.5. Incorporation of PEG-lipids into preformed liposomes
The incorporation of sterol–PEG1300 or MPEG2000–DSPE into EPC/Chol,
HSPC/Chol and HSPC/Chol/MPEG2000–DSPE liposomes was followed by
1H
NMR, which is similar to the experimental setup described by Sou et al. [23].
For calibration, 200 μl of a 50 mM liposome dispersion (phospholipid
content adjusted after phosphorus colorimetric assay [29]) was mixed with
varying amounts of sterol–PEG1300 or MPEG2000–DSPE in HBS. This resulted
in an amount between 0.07 and 10 mol% PEG-lipid referring to total lipid (TL,
sterol–PEG1300 not included). Samples were adjusted to 1.5 g with aqueous 50
mM NaCl solution, freeze-dried (Lyovac GT 2, Finn Aqua, Huerth, Germany),
redissolved in CDCl3, then centrifuged for the removal of precipitated NaCl to
avoid peak broadening if necessary, before 1H NMR spectra (Varian U-300,
Varian, Palo Alto, USA) were recorded. Calibration was obtained by linear
regression of mol% PEG-lipid vs. the peak area ratio (determined using MestRe-
C software) of the methylene proton of PEG (3.6–3.7 ppm) to the choline
methylene proton of EPC or HSPC (3.35–3.4 ppm).
For the measurement of incorporation kinetics, 500 μl containing finally 7.5
mol% of TL of sterol–PEG1300 or MPEG2000–DSPE were added to 1000 μl ofthe liposome dispersions (50 mM) at 21±0.5 °C. After the appropriate
incubation times, samples (300 μl) were taken and free PEG-lipid was separated
from liposomal associated PEG-lipids by size exclusion chromatography using
a Sepharose CL-4B column (12×1.5 cm) equilibrated with 50 mM NaCl.
Fractions containing most of the liposomes were pooled, adjusted to 1.5 g with
50 mM NaCl and treated according to the calibrators. The amount of PEG-lipid
transferred into the vesicles was calculated from the calibration data (R2N0.99)
and was expressed as the percentage of total PEG-lipid injected into the
liposome dispersion.
2.6. Preparation of the protein-anchor conjugate
In order to assay the suitability of sterol–PEG1300–TRE as an anchor for
subsequent attachment of targeting devices to liposomes, a simple standard
coupling procedure was established with BSA as a model protein.
10 μl of methanolic solutions of 0.489 μmol (915 μg) sterol–PEG1300–TRE
were dried in 1.5 ml reaction vials by spin evaporation (Concentrator 5301,
Eppendorf, Wesseling-Berzdorf, Germany) or by high vacuum (Pb0.05 mbar).
The sterol–PEG1300–TRE-coated vials were stored at −27 °C.
For coupling experiments varying amounts of BSA were dissolved in 100
mMborate buffer pH 8.4. Theywere then labelled with approximately 10 kBq of
125I-labelled BSA, which was prepared using the IODO-bead method (Pierce,
Rockford, USA) and purified on Sephadex-G25 (Pharmacia, Uppsala, Sweden),
followed by dialysis overnight using a highly permeable 10 kDa cut-off
cellulose membrane (Dianorm Munich, Germany).
After this step 150 μl of labelled BSA solution were pipetted into each of the
sterol–PEG1300–TRE-coated vials, bath sonicated (Sonorex RK 106 S,
Bandelin, Berlin, Germany) for 30 s and then vortexed for 30 s. To determine
the coupling efficiency, the derivatization of the protein (first incubation step)
was allowed to continue at room temperature overnight.
2.7. Insertion of the protein-anchor conjugate into preformed
liposomes
Attachment of BSA to the liposomes (second incubation step) was initiated
by the addition of 300 μl of a 20 mM liposome dispersion resulting in 7.5 mol%
sterol–PEG1300–TRE of TL. The mixture was incubated for at least 4 h at room
temperature in order to allow the incorporation to proceed.
Thereafter, a 300-μl sample was taken and free (125I labelled) BSA was
separated from liposomal bound BSA on Sepharose 4B-CL. The amount of BSA
attached to EPC, HSPC and sterically stabilized HSPC liposomes was calculated
by counting the radioactivity of each fraction, using the unfractionated liposome
dispersion as a reference.
Focussing on the kinetics of the reaction of sterol–PEG1300–TRE with
BSA, the derivatization during the first incubation step was terminated by the
addition of 100 μl of an aqueous solution of histidine–HCl (pH approxi-
mately 4.5). This solution contained an 80-fold molar excess over the moles
of amino groups provided by BSA (0.5 mg/ml, borate buffer) before pre-
formed EPC-liposomes were added for the second incubation step, which
lasted overnight.
2.8. Liposome leakage during incorporation of the sterol derivatives
For quantification of liposome leakage induced by incorporation of sterol–
PEG1300–proteins into preformed liposomes of different membrane composi-
tions, dried lipid films were hydrated with 50 mM calcein solution (self-
quenching concentration) in HBS, pH 7.4, resulting in a 50 mM liposome raw
dispersion. After three freeze/thaw cycles liposomes were sized as described
above. Non-encapsulated calcein was separated from calcein liposomes on a
Sepharose CL-4B column. Liposomes were adjusted to 10 mM lipid by addition
of HBS. Protein–sterol–PEG1300-conjugates were prepared as described in
Section 2.6. Calcein loaded liposomes were added to the conjugates to yield a
final amount of 7.5 mol% sterol–PEG1300 of the total lipid. Leakage was
followed by measuring fluorescence increase at λex 470 nm and λem 510 nm
(LS-50B Perkin Elmer, Buckinghamshire, UK). When no further increase of
fluorescence could be observed, 2 μl samples of the mixture were taken and the
final percentage of dye released was determined. A calcein release of 100% was
23T. Steenpaß et al. / Biochimica et Biophysica Acta 1758 (2006) 20–28obtained by lysing the liposomes with 10 μl of 10% (m/m) Triton X-100 in
deionised water. Calcein release was calculated as
% calceinfree ¼ It  I0Il  I0 d100
where It is the fluorescence intensity after incubation of liposomes for the
desired period of time, I0 the fluorescence baseline intensity and I∞ the
fluorescence after liposomes lysis. Basal release of calcein from the different
liposome species was monitored for at least 6 h, and turned out to be negligible.
The linearity of fluorescence intensity vs. released calcein concentration was
controlled in a parallel experiment.
2.9. In vitro stability of liposome modification in human serum
The stability of membrane anchoring and covalent linkage between BSA and
sterol–PEG1300 was investigated by incubating surface modified liposomes in
human plasma (50% v/v) at 37 °C for 20 h. The amount of 125I-BSA dissociated
from the vesicles was determined by chromatography on Sepharose CL-4B in
HBS according to Ishida et al. [19].
2.10. Cryo electron microscopy
Cryo electron microscopic studies of the aggregation behaviour of liposomes
and sterol–PEG1300–BSA were performed as described elsewhere [30].
3. Results and discussion
Using plain or sterically stabilized liposomes a novel method
was developed for coupling BSA, as a model protein, to
liposomes. The method consists of three simple steps. Sterol–
PEG1300 is activated by tresylation. To the formed sterol–
PEG1300–TRE (Fig. 2a), protein is covalently bound at pH 8.4
resulting in sterol–PEG1300–protein molecules (Fig. 2c), which
then spontaneously and effectively insert into the outer
membrane of preformed liposomes to yield functionalized
liposomes (Fig. 2e). To better understand the various steps of
this novel method, we looked at a number of aspects. These
included the kinetics of the coupling reaction and insertion, the
occurrence of possible membrane disturbances during the
insertion step, as well as the stability of protein attachment to
liposomes.Fig. 2. Protein coupling by the tresyl method: Tresylated sterol–PEG1300 (sterol–PEG
BSA (b) at pH 8.4 in order to form sterol–PEG1300–BSA (c). Liposomes (d) are then
room temperature.3.1. Kinetics of insertion of PEG-lipids
Insertion kinetics of PEG-sterols and PEG-phospholipids
into liposome membranes was determined in order to get infor-
mation about the time-scale of steric stabilization of preformed
liposomes, as well as the insertion of activated lipids or protein–
lipid-conjugates. The transfer of 2.7 mM sterol–PEG1300 or
MPEG2000–DSPE at 21±0.5 °C into the vesicle membranes
(33.3 mM lipid) with different lipid compositions was followed
by 1H NMR after separating free from liposomally bound PEG-
lipid at different time points on Sepharose CL-4B.
As shown in Fig. 3A, the addition of 2.7 mM sterol–PEG1300
(7.5mol%of total lipid, i.e. 35.8mM, includingPEGlipids) to the
liposome dispersion leads to almost complete incorporation of
the sterol–PEG1300 in the case of EPC membranes. However,
only approximately 40% or 30% were inserted into HSPC/Chol
or sterically stabilized HSPC/Chol liposomes, respectively (Fig.
3A). The different amount of insertion of sterol–PEG1300 into
membranes could be explained by different loading capacities for
fluid and rigidmembranes.As theCMCvalue for sterol–PEG1300
is 3 μM [31], the insertion of the added PEG-lipids at almost
1000-fold CMC occurs from coexistingmicelles and monomers.
The insertion of the sterol anchor into the different liposome
species takes place very rapidly, reaching equilibrium within
15–30 min. Since insertion of entire micelles into the membrane
is improbable, the rapid kinetics point to rapid demicellization
of sterol–PEG1300 and insertion of the monomeric PEG-lipid.
The rate of insertion of BSA-PEG lipids was estimated by
incubating sterol–PEG1300–BSAwith EPC/Chol (7:3 mol/mol)
liposomes. After 1 min of incubation followed by separation of
the non-inserted BSA by column chromatography almost 80%
of the BSAwas attached to the membrane, which would suggest
very fast and efficient membrane insertion of the albumin-
linked PEG sterol.
Interestingly, 5 mol% MPEG2000–DSPE present in the vesi-
cles has only a minor inhibiting effect on anchor insertion,
suggesting that even subsequent protein attachment to sterically
stabilized liposomes is possible. Additional insertion into1300–TRE), coexisting in solution as monomers and in micelles (a) is coupled to
added to the conjugates, which insert into the outer liposome monolayer (e) at
Fig. 4. Calcein release from liposomes 6 h after mixing with sterol–PEG1300–
BSA (7.5 mol% of TL) at room temperature.
Fig. 3. Incorporation kinetics of PEGylated lipids at room temperature into
liposomes composed of: ■ EPC/Chol (7/3 mol/mol); ▴ HSPC/Chol (2/1 mol/
mol) or ● HSPC/Chol/MPEG2000–DSPE (2/1/0.16 mol/mol/mol) followed by
1H NMR. Values of membrane inserted PEG–lipids are given as the percentage
of the added amount (7.5%) of total lipid. A, sterol–PEG1300; B, MPEG2000–
DSPE. Mean of three experiments±S.D.
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micellar IgG-PEG2000–DSPE as well. However, even at
elevated temperature a very low degree of insertion has been
reported [19,20].
In our study, the amount of MPEG2000–DSPE transferred to
preformed vesicles at room temperature was found to be very
small (Fig. 3B), independent of membrane fluidity. After 4 h of
incubation, less than 3% were co-eluted with the vesicles for
EPC/Chol and 2% for HSPC/Chol liposomes of the MPEG2000–
DSPE. This resulted in a total PEG–lipid ratio of less than 0.2
mol% of TL in the outer membrane monolayer. The different
degrees of insertion for both components is not caused by a
difference in initial concentrations of monomers coexisting with
the micelles because CMC values are around 5 μM in each case.
Sterical hindrance of the two flexible fatty acid moieties may
contribute to the lower amount of insertion of MPEG2000–DSPE
as compared to that seen with sterol–PEG1300. The sterol–
PEG1300 molecule contains a rigid, single portion, which can
overcome the water–membrane interface more easily. However,
considering the rapid insertion of approximately 2% of addedMPEG2000–DSPE in Fig. 6, it is more probable that the acti-
vation energy of demicellization is much higher and/or its
kinetics are much slower than that of sterol–PEG1300.
3.2. Leakage during incorporation
The accumulation of the sterol anchor, which is initially most
likely restricted to the outer leaflet of the liposomes, can induce
membrane tensions due to differing lipid amounts in the two
monolayers [32]. This effect may cause significant loss of
encapsulated material by provoking membrane reorganization.
As shown in Fig. 4, the release of calcein after mixing with
sterol–PEG1300–BSA (7.5 mol% of TL) is at maximum 5%
from EPC liposomes with high membrane fluidity and in the
order of 1–3% for plain or sterically stabilized rigid HSPC
liposomes. Maximum release was reached 30 min after addition
of the protein–sterol conjugate and then remained essentially
constant.
The release rate of calcein from liposomes exposed to sterol–
PEG1300–BSA amounts to up to 7.5 mol% of TL, which is
convenient for protein attachment, is comparable to the release
rate found for doxorubicin [19] or carboxyfluorescein [24]
when using the post insertion technique.
3.3. Protein attachment to preformed liposomes
The activation of hydroxyl groups by tresylation was
introduced by Nilsson and Mosbach [28] and has become a
widely used method for PEGylation of proteins [33–35] and
other amine-containing materials [36,37]. The coupling of
tresylated PEGwas formerly believed to take place by alkylation
of amino groups [28], resulting in a secondary amide bond to the
protein to be coupled (Fig. 1e). Later studies suggested an
alternative route of PEGylation of the protein forming a sulfo-
acetamide linkage [38,39] to the proteins to be modified (Fig.
1d). While the secondary amide is stable in vitro and in vivo,
sulfonyl linkages may be subject to slow hydrolytic cleavage.
Furthermore, the formation of the stable secondary amine
Fig. 6. Absolute (A) amount of BSA (μg protein/total lipid) and (B) relative
amount (% of total BSA) coupled to different liposome preparations (20 mmol
lipid/l) depending on the protein concentration during the first incubation step,
after addition of sterol–PEG1300–BSA to pre-formed liposomes.
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therefore may not decrease the biological function to the same
extent as the alternative sulfoacetamide bond [40]. As
carbamate, p-nitrophenylcarbonyl [16] or amide bonds, result-
ing from other amine-reactive coupling procedures also
eliminate the positive charge, the coupling of proteins to
liposomes may result in more effective ligand receptor
interaction when tresyl-activated lipids are used for their
attachment. Since pH values slightly above 8 are most
favourable for achieving high rates of secondary amide bonds
[39], the coupling of protein to sterol–PEG1300–TRE was
performed in borate buffered solution at pH 8.4.
As shown in Fig. 5, more than 50% of the radioactive labelled
protein is coupled to the activated sterol–PEG1300 within 1 h.
After 12 h the reaction is almost completed.
3.4. Coupling efficiency
The absolute amount of sterol–PEG1300–BSA, which is
attachable to different liposome types as a function of protein
concentration during the first incubation step is shown in Fig. 6.
Protein:lipid ratio (mol/mol) of the final liposome dispersions
during coupling experiments reached from 1:2700 (1 mg/ml
BSA during first incubation step) to 1:540 (5 mg/ml), which is
similar to the conditions used for antibody coupling (1:1000) as
described in [17,41].
Although the relative coupling efficiency decreases (Fig. 6)
with increasing concentrations of the protein to be coupled, the
subsequent grafting of proteins via tresylated sterol–PEG1300
easily allows protein densities necessary for targeting purposes
[42]. Because an antibody density above 75 μg/μmol of TL was
reported to accelerate the clearance of sterically stabilized
immunoliposomes [15], and keeping in mind that the molar
mass of antibodies is more than 2-fold higher than that of BSA,
one could calculate that the protein/lipid ratio of 1:2000 shouldFig. 5. Binding efficiency of BSA to liposomes depending on the reaction time
between BSA (0.5 mg/ml) and 7.5 mol% (of TL) of sterol–PEG1300–TRE. The
coupling reaction of protein and sterol–PEG1300–TRE was terminated at
different times by addition of a molar excess of amino-groups, before the BSA-
conjugate was mixed with vesicles and incubated for 2 h. Mean of three
experiments±S.D.supply sufficient coupling efficiency in the case of antibody
coupling.
Since the quantity of sterol–PEG1300–TREwas kept constant
over all coupling experiments, the ratio of protein supplemented
amino groups to activated lipid becomes more and more un-
favourable as protein concentration increases.
For the highest protein concentration used during coupling
experiments a 43-fold molar excess of activated lipid results in
0.62 sterol–PEG1300–TRE anchors per lysine of BSA. There-
fore, it can be supposed that every BSA molecule bears several
sterol-anchors and is multiply linked to the liposome.
In this context, it may be understandable that the differences
in the level of protein grafting of the varying liposome types is
less pronounced than may be assumed from the amount of
sterol–PEG1300 incorporated (see Fig. 3A). The number of sterol
anchors accepted by the sterically stabilized vesicles seems to be
sufficient for a stable protein–liposome linkage.
3.5. Increase of particle size
Upon incubation of liposomes with BSA bearing several
sterol anchors, the linkage of liposomes and the resulting in-
crease in particle size is unavoidable. This problem of liposome
cross-linking is rarely discussed in the literature, even though it
has a high probability of occurring with each coupling tech-
nique. Table 1 illustrates that size increase is dependent on
protein amount and liposome composition as a function of time.
As expected, increasing protein amounts favours the formation
of liposome aggregates. In some cases particle diameters are
two-fold larger, which would suggest the covalent linkage of
several liposomes via the protein molecules bearing several
PEG–sterol moieties. The structure of such aggregates is shown
in a representative cryo-EM picture (Fig. 7). Besides some
isolated vesicles, most of the liposomes are tightly connected. At
an aggregation number of more than four, the aggregates become
Table 1
Increase of particle size (hydrodynamic diameter in nm) during the incorporation of sterol–PEG1300–proteins into different liposome types
BSA [mg/
ml]
EPC/Chol HSPC/Chol HSPC/Chol/MPEG
0 1 5 0 1 5 0 1 5
z-Av
Initial 116.2±1.38 124.3±1.45 119.6±2.13 112.6±1.67 113.5±1.14 111.9±1.02 118.7±1.13 119.4±1.12 118.6±1.45
4 h – 170.1±3.46 374.3±3.21 – 121.8±1.73 228.1±2.51 – 130.3±5.82 172.6±2.7
12 h 118.2±1.56 209.9±10.61 816.2±18.4 115.3±2.31 120.5±1.91 335.0±11.72 119.2±1.13 136.0±3.11 226.6±3.6
PI
Initial 0.1±0.01 0.11±0.03 0.09±0.04 0.06±0.02 0.05±0.04 0.06±0.02 0.09±0.01 0.06±0.02 0.1±0.01
4 h – 0.12±0.02 0.28±0.01 – 0.04±0.02 0.2±0.1 – 0.12±0.01 0.26±0.03
12 h 0.098±0.02 0.2±0.01 0.56±0.09 0.076±0.02 0.06±0.04 0.31±0.02 0.083±0.01 0.11±0.01 0.38±0.02
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and also show flattened areas formed by cross-linked bilayers.
Cryo studies of control preparations of plain liposomes with or
without the insertion of non-activated sterol–PEG showed that
these liposomes were essentially non-aggregated (not shown).
Particle size can be limited by the rapid usage of the function-
alized liposomes. Alternatively, modification of the liposome
surface using 7.5% sterol–PEG1300 during vesicle preparation or
by subsequent insertion into plain liposomes leads to a stabi-
lization of particle size during the second incubation step (data
not presented). After 12 h of incubation of the sterol–PEG1300
modified liposomes (EPC/Chol 20 mM, z-Average: 120.4) with
the sterol–PEG1300–protein conjugate (c BSA: 1 mg/ml) a par-
ticle size of approximately 160 nm was reached and this did not
significantly change over a period of 48 h.
3.6. Stability of protein attachment
Investigating the stability of the protein linkage in the
presence of serum, BSA coupled liposomes were rechromato-Fig. 7. Cryo electron microscopic picture of single liposomes and aggregates
formed after incubating sterol–PEG1300–BSA (5 mg/ml BSA) with EPC/
cholesterol liposomes for 4 h. Flat connection areas and spaces between
membranes in larger aggregates (middle and bottom left) indicate the covalent
linkage of liposomes by sterol–PEG–BSA.graphed after incubation for 20 h at 37 °C in 50% (v/v) human
serum. Dissociated 125I-labelled protein was not detectable in
any of the preparations, suggesting a covalent attachment which
is stable with regards to enzymatic stress, as well as a hydro-
phobic anchoring in the membrane which is resistant to inter-
ference by serum.
4. Conclusion
The novel and simple method presented here is suitable to
functionalize plain or even PEGylated liposomes. In the standard
protocol used to couple proteins such as BSA as a model ligand,
in a first step sterol–PEG1300 is activated by tresylchloride at 0
°C for 4 h to give sterol–PEG1300–TRE, which can be stored
until use. In a second step, sterol–PEG1300–TRE reacts quanti-
tatively with proteins in an aqueous solution at pH 8.4 within 2–
4 h, forming sterol–PEG1300–protein conjugates, which in a
third step spontaneously insert into preformed liposomes at
room temperature. The amount of membrane leakage during the
grafting process is negligible. This method can be used for the
functionalization of plain fluid or rigid membranes and also of
PEGylated liposomes. In contrast to conventional coupling proce-
dures, the derivatization of the protein takes place in the absence
of membrane lipids and encapsulated material, which avoids
interference by the activated lipids with these compounds. An
additional advantage of the post-functionalization method is the
modification of liposomes at room temperature, which avoids
denaturation of encapsulated or attached biomacromolecules.
In preliminary experiments in mice, post-functionalized
liposomes show a half-life in the circulation of approximately
4 h. The shorter circulation time as compared to that seen with
MPEG2000–DSPE is probably due to the shorter length of the
PEG-1300 moiety, rather than to instability of the anchoring of
the lipid in the membrane. The strength of membrane
anchoring of sterol–PEG seems to be of minor importance
as seen with the results of incubating the post-functionalized
liposomes with serum. However, further studies in animals
using double-labelled protein-bearing liposomes can clarify if
other destabilization or cleaving reactions occur under in vivo
conditions.
The prolonged blood circulation compared to conventional
liposomes should be sufficient, when targeting cells such as
granulocytes and monocytes, which are both resident in tissues
as well as circulating the blood. Therefore, with the presented
27T. Steenpaß et al. / Biochimica et Biophysica Acta 1758 (2006) 20–28method specific targeting of liposome encapsulated protein like
glucose oxidase [2] to phagocytes of blood and tissue should
be possible. Furthermore, the described method may allow
functionalization of polymerized liposomes [43], thus avoiding
possible interference between the techniques for coupling and
polymerization.
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